Advances in the research of the drugs targeting glucagon-like peptide-1 receptor
LI Gai-na
SHEN Zhu-fang
Abstract：Glucagon-like peptide-1 (GLP-1) ,a 30 amino-acid peptide,is an incretin secreted from the in-testinal L cells. It can bind to the GLP-1 receptor to exert a variety of anti-diabetic activity. However,its half-life is only about 2 min in vivo,which may limit its application in clinic. Even though,GLP-1 receptor remains to be a new target for the research and development of anti-diabetic drugs. The aim is to discover long-term peptidic or non-pep-tidic glucagon-like peptide-1 receptor agonists,which could also resist the degradation by dipeptidyl peptidase IV (DPP IV).Up to date,besides of exenatide that has been approved by US Food Drug Administration ( FDA ) ,there are some peptides,such as liraglutide,in clinic study state and many other peptidic or non-peptidic compounds in pre-clinic study state. In this article,we reviewed the recent achievements regarding drugs targeting GLP-1 receptor.
Keywords：glucagon-like peptide-1 receptortargeted drugsexenatideliraglutide
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 2219-2222,2232 )